67184 Federal Register / Vol. 70, No. 213 / Friday, November 4, 2005 / Notices 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Technologies for Environmental Monitoring. 

Date: November 18, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Select Bethesda, 8120 

Wisconsin Ave., Bethesda, MD 20814. 

Contact Person: Alexander Gubin, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4196, 

MSC 7812, Bethesda, MD 20892, 301–435–

2902, gubina@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflicts: Stress Reduction and Lifestyle 

Changes to Prevent Disease. 

Date: November 22, 2005. 

Time: 12:30 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Karen Lechter, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3128, 

MSC 7759, Bethesda, MD 20892, 301–496–

0726, lechterk@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Inflammatory HDL. 

Date: December 1, 2005. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Joyce C. Gibson, DSC, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4130, 

MSC 7814, Bethesda, MD 20892, 301–435–

4522, gibsonj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Serotonin 

and Vascular Tone. 

Date: December 6, 2005. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Joyce C. Gibson, DSC, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4130, 

MSC 7814, Bethesda, MD 20892, 301–435–

4522, gibsonj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Ischemia 

Reperfusion Injury. 

Date: December 7, 2005. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Rajiv Kumar, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4122, 

MSC 7802, Bethesda, MD 20892, 301–435–

1212, kumarra@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Bioengineering Research Partnerships. 

Date: December 8, 2005. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Select Bethesda, 8120 

Wisconsin Ave, Bethesda, MD 20814. 

Contact Person: Khalid Masood, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5095H, 

MSC 7854, Bethesda, MD 20892, 301–402–

3962, masoodk@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Angiotensin 

Receptors. 

Date: December 8, 2005. 

Time: 2 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Joyce C. Gibson, DSC, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4130, 

MSC 7814, Bethesda, MD 20892, 301–435–

4522, gibsonj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Small 

Business Orthopedic Medicine. 

Date: December 8–9, 2005. 

Time: 6 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Wyndham Washington, DC., 1400 M 

Street, NW., Washington, DC 20005. 

Contact Person: Richard J. Bartlett, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4110, 

MSC 7814, Bethesda, MD 20892, 301–435–

6809, bartletr@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 28, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–21993 Filed 11–3–05; 8:45am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908), 

on September 30, 1997 (62 FR 51118), 

and on April 13, 2004 (69 FR 19644). 

A notice listing all currently certified 

laboratories is published in the Federal 

Register during the first week of each 

month. If any laboratory’s certification 

is suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end, 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http://workplace.samhsa.gov 

and http://www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh or Dr. Walter Vogl, 

Division of Workplace Programs, 

SAMHSA/CSAP, Room 2–1035, 1 Choke 

Cherry Road, Rockville, Maryland 

20857; 240–276–2600 (voice), 240–276–

2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Public Law 

100–71. Subpart C of the Mandatory 

Guidelines, ‘‘Certification of 

Laboratories Engaged in Urine Drug 

Testing for Federal Agencies,’’ sets strict 

standards that laboratories must meet in 

order to conduct drug and specimen 

validity tests on urine specimens for 

Federal agencies. To become certified, 

an applicant laboratory must undergo 

three rounds of performance testing plus 

an on-site inspection. To maintain that 

Federal Register / Vol. 70, No. 213 / Friday, November 4, 2005 / Notices 67185 

certification, a laboratory must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories which claim to be in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A laboratory 

must have its letter of certification from 

HHS/SAMHSA (formerly: HHS/NIDA) 

which attests that it has met minimum 

standards. 

In accordance with Subpart C of the 

Mandatory Guidelines dated April 13, 

2004 (69 FR 19644), the following 

laboratories meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328–

7840 / 800–877–7016, (Formerly: 

Bayshore Clinical Laboratory) 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770 / 888–290–

1150 

Aegis Analytical Laboratories, Inc., 345 

Hill Ave., Nashville, TN 37210, 615–

255–2400 

Baptist Medical Center-Toxicology 

Laboratory, 9601 I–630, Exit 7, Little 

Rock, AR 72205–7299, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center) 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800–

445–6917 

Diagnostic Services, Inc., dba DSI, 

12700 Westlinks Drive, Fort Myers, 

FL 33913, 239–561–8200 / 800–735–

5416 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602, 229–671–

2281 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974, 

215–674–9310 

Dynacare Kasper Medical Laboratories*, 

10150–102 St., Suite 200, Edmonton, 

Alberta, Canada T5J 5E2, 780–451–

3702 / 800–661–9876 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662–

236–2609 

Express Analytical Labs, 3405 7th Ave., 

Suite 106, Marion, IA 52302, 319–

377–0500 

Gamma-Dynacare Medical 

Laboratories*, A Division of the 

Gamma-Dynacare, Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519–

679–1630 

General Medical Laboratories, 36 South 

Brooks St., Madison, WI 53715, 608–

267–6225 

LabOne, Inc., 10101 Renner Blvd., 

Lenexa, KS 66219, 913–888–3927/ 

800–873–8845, (Formerly: Center for 

Laboratory Services, a Division of 

LabOne, Inc.) 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984, 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group) 

Laboratory Corporation of America 

Holdings, 10788 Roselle St., San 

Diego, CA 92121, 800–882–7272, 

(Formerly: Poisonlab, Inc.) 

Laboratory Corporation of America 

Holdings, 550 17th Ave., Suite 300, 

Seattle, WA 98122 , 206–923–7020/ 

800–898–0180, (Formerly: DrugProof, 

Division of Dynacare/Laboratory of 

Pathology, LLC; Laboratory of 

Pathology of Seattle, Inc.; DrugProof, 

Division of Laboratory of Pathology of 

Seattle, Inc.) 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339, (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center) 

Marshfield Laboratories, Forensic 

Toxicology Laboratory, 1000 North 

Oak Ave., Marshfield, WI 54449, 715–

389–3734/800–331–3734 

MAXXAM Analytics Inc.*, 6740 

Campobello Road, Mississauga, ON, 

Canada L5N 2L8, 905–817–5700, 

(Formerly: NOVAMANN (Ontario), 

Inc.) 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244 

MetroLab-Legacy Laboratory Services, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725–

2088 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304, 661–322–4250/800–350–3515 

Northwest Toxicology, a LabOne 

Company, 2282 South Presidents 

Drive, Suite C, West Valley City, UT 

84120, 801–606–6301/800–322–3361, 

(Formerly: LabOne, Inc., dba 

Northwest Toxicology; NWT Drug 

Testing, NorthWest Toxicology, Inc.; 

Northwest Drug Testing, a division of 

NWT Inc.) 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504, 888–747–3774, (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory) 

Oregon Medical Laboratories, P.O. Box 

972, 722 East 11th Ave., Eugene, OR 

97440–0972, 541–687–2134 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942, (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory) 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204, 509–755–8991/ 

800–541–7897x7 

Physicians Reference Laboratory, 7800 

West 110th St., Overland Park, KS 

66210, 913–339–0372/800–821–3627 

Quest Diagnostics Incorporated, 3175 

Presidential Dr., Atlanta, GA 30340, 

770–452–1590/800–729–6432, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories) 

Quest Diagnostics Incorporated, 4770 

Regent Blvd., Irving, TX 75063, 800–

824–6152, (Moved from the Dallas 

location on 03/31/01; Formerly: 

SmithKline Beecham Clinical 

Laboratories; SmithKline Bio-Science 

Laboratories) 

Quest Diagnostics Incorporated, 4230 

South Burnham Ave., Suite 250, Las 

Vegas, NV 89119–5412, 702–733–

7866/800–433–2750, (Formerly: 

Associated Pathologists Laboratories, 

Inc.) 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories) 

Quest Diagnostics Incorporated, 506 E. 

State Pkwy., Schaumburg, IL 60173, 

800–669–6995/847–885–2010, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; International 

Toxicology Laboratories) 

Quest Diagnostics Incorporated, 7600 

Tyrone Ave., Van Nuys, CA 91405, 

818–989–2520/800–877–2520, 

(Formerly: SmithKline Beecham 

Clinical Laboratories) 

67186 Federal Register / Vol. 70, No. 213 / Friday, November 4, 2005 / Notices 

Scientific Testing Laboratories, Inc., 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130 

Sciteck Clinical Laboratories, Inc., 317 

Rutledge Road, Fletcher, NC 28732, 

828–650–0409 

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109, 505–

727–6300/800–999–5227 

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, 

IN 46601, 574–234–4176 x276 

Southwest Laboratories, 4645 E. Cotton 

Center Boulevard, Suite 177, Phoenix, 

AZ 85040, 602–438–8507/800–279–

0027 

Sparrow Health System, Toxicology 

Testing Center, St. Lawrence Campus, 

1210 W. Saginaw, Lansing, MI 48915, 

517–364–7400, (Formerly: St. 

Lawrence Hospital & Healthcare 

System) 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., 

Oklahoma City, OK 73101, 405–272–

7052, 

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 

70 West, Suite 208, Columbia, MO 

65203, 573–882–1273 

Toxicology Testing Service, Inc., 5426 

N.W. 79th Ave., Miami, FL 33166, 

305–593–2260 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755–

5235, 301–677–7085 

*The Standards Council of Canada (SCC) 

voted to end its Laboratory Accreditation 

Program for Substance Abuse (LAPSA) 

effective May 12, 1998. Laboratories certified 

through that program were accredited to 

conduct forensic urine drug testing as 

required by U.S. Department of 

Transportation (DOT) regulations. As of that 

date, the certification of those accredited 

Canadian laboratories will continue under 

DOT authority. The responsibility for 

conducting quarterly performance testing 

plus periodic on-site inspections of those 

LAPSA-accredited laboratories was 

transferred to the U.S. HHS, with the HHS’

NLCP contractor continuing to have an active 

role in the performance testing and 

laboratory inspection processes. Other 

Canadian laboratories wishing to be 

considered for the NLCP may apply directly 

to the NLCP contractor just as U.S. 

laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on April 13, 2004 (69 FR 

19644). After receiving DOT 

certification, the laboratory will be 

included in the monthly list of HHScertified laboratories and participate in 

the NLCP certification maintenance 

program. 

Anna Marsh, 

Director, Office Program Services, SAMHSA. 

[FR Doc. 05–21801 Filed 11–3–05; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Notice and request for 

comments. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA) has 

submitted the following information 

collection to the Office of Management 

and Budget (OMB) for review and 

clearance in accordance with the 

requirements of the Paperwork 

Reduction Act of 1995. The submission 

describes the nature of the information 

collection, the categories of 

respondents, the estimated burden (i.e., 

the time, effort and resources used by 

respondents to respond) and cost, and 

includes the actual data collection 

instruments FEMA will use. 

Title: The National Flood Insurance 

Program—Biennial Report. 

OMB Number: 1660–0003. 

Abstract: The NFIP Biennial Report 

enables FEMA to meet its regulatory 

requirement under 44 CFR 59.22(b)(2). It 

also enables FEMA to be more 

responsive to the ongoing changes that 

occur in each participating community’s 

flood hazard area. These changes 

include, but are not limited to, new 

corporate boundaries, changes in flood 

hazard areas, new floodplain 

management measures, and changes in 

rate of floodplain development. It is also 

used to evaluate the effectiveness of the 

community’s floodplain management 

activities. The evaluation is 

accomplished by analyzing information 

provided by the community, such as the 

number of variances and flood plain 

permits granted by each community in 

relationship to other information 

contained in the Biennial Report, as 

well as other data available in FEMA’s 

Community Information System (CIS). 

The Biennial Report also provides an 

opportunity for the National Flood 

Insurance Program (NFIP) participating 

communities to request technical 

assistance in implementing a floodplain 

management program. FEMA regional 

offices use this information as a means 

to know which communities need 

support and guidance. In addition, the 

NFIP Biennial Report is one of the tools 

used to assist FEMA in meeting its 

regulatory requirement under section 

575 of the National Flood Insurance 

Reform Act of 2004. A ‘‘yes’’ answer to 

Items A–D in Section I of the report will 

provide the basis for FEMA to follow-up 

by contacting the community for 

clarification and/or elaboration 

regarding changes and activities 

occurring in a community’s flood 

hazard area. This information will be 

used in ranking and prioritizing one 

community’s mapping needs against all 

other communities in the NFIP and for 

determining how the limited flood 

hazard mapping funds are allocated for 

map updates. 

Affected Public: State, local and 

Tribal governments. 

Number of Respondents: 20,500 

respondents. 

Estimated Time per Respondent: 2.49 

hours. 

Estimated Total Annual Burden 

Hours: 11,375. 

Frequency of Response: Every two 

years. 

Comments: Interested persons are 

invited to submit written comments on 

the proposed information collection to 

the Office of Information and Regulatory 

Affairs at OMB, Attention: Desk Officer 

for the Department of Homeland 

Security/FEMA, Docket Library, Room 

10102, 725 17th Street, NW., 

Washington, DC 20503, or facsimile 

number (202) 395–7285. Comments 

must be submitted on or before 

December 5, 2005. 

FOR FURTHER INFORMATION CONTACT: 

Requests for additional information or 

copies of the information collection 

should be made to Chief, Records 

Management, FEMA, 500 C Street, SW., 

Room 316, Washington, DC 20472, 

facsimile number (202) 646–3347, or 

e-mail address FEMA-InformationCollections@dhs.gov. 

Dated: October 28, 2005. 

Darcey Bingham, 

Branch Chief, Information Resources 

Management Branch, Information 

Technology Services Division. 

[FR Doc. 05–22061 Filed 11–3–05; 8:45 am] 

BILLING CODE 9110–12–P